Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|13|2|76-84

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.13, Iss.2, 2018-05, pp. : 76-84

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

By Scagliotti Giorgio  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2855-2866

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of Erlotinib versus Docetaxel for Second-line Treatment of Advanced Non-small-cell Lung Cancer in the United Kingdom

By Lewis G   Peake M   Aultman R   Gyldmark M   Morlotti L   Creeden J   de la Orden M  

The Journal of International Medical Research, Vol. 38, Iss. 1, 2010-01 ,pp. : 9-21

Field House Publishing

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer

By Holmes J.  

PharmacoEconomics, Vol. 22, Iss. 9, 2004-01 ,pp. : 581-589

Adis International

Access to resources Recommend Favorite

The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer

By  

Current Clinical Pharmacology, Vol. 12, Iss. 1, 2017-06 ,pp. : 4-10

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 58-60

Bentham Science Publishers

Access to resources Recommend Favorite